KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) EBITDA (2017 - 2025)

Historic EBITDA for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $70.3 million.

  • Amneal Pharmaceuticals' EBITDA fell 2079.18% to $70.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $357.9 million, marking a year-over-year increase of 9062.68%. This contributed to the annual value of $249.3 million for FY2024, which is 2199.5% up from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' EBITDA stood at $70.3 million, which was down 2079.18% from $111.4 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year EBITDA high stood at $111.4 million for Q2 2025, and its period low was -$198.6 million during Q2 2022.
  • Its 5-year average for EBITDA is $41.8 million, with a median of $45.9 million in 2021.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' EBITDA surged by 107104.72% in 2021, and later crashed by 39591.92% in 2022.
  • Amneal Pharmaceuticals' EBITDA (Quarter) stood at $11.2 million in 2021, then surged by 222.43% to $36.0 million in 2022, then plummeted by 60.61% to $14.2 million in 2023, then skyrocketed by 434.02% to $75.8 million in 2024, then fell by 7.19% to $70.3 million in 2025.
  • Its EBITDA was $70.3 million in Q3 2025, compared to $111.4 million in Q2 2025 and $100.3 million in Q1 2025.